Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

已完结 20 由达姆发布于 2026/1/15 15:47:31

DOI:10.1158/0008-5472.can-24-3891
作者：Sarah K Herzog,Jessica H Stevens,Guowei Gu,Sandra L Grimm,Kloma Cardoza,Autumn G M Hawkins,Hangqing Lin,Daniela Ramos,Amanda R Beyer,David G Edwards,Derek Dustin,Harry J Yang,Nicole Liang,Ashfia F Kha
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：ESR1 mutations are the leading cause of endocrine therapy resistance and progression in ER-positive metastatic breast cancer. ESR1 mutations are detected in ~50% of metastatic breast cancer

应助信息

1天前

yangxiang

2afa20c0f1e811f0b9aa34735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/1/15 15:47:31 未找到该文献，机器人已退出，请等待人工下载

2026/1/15 15:47:31 Book学术AI机器人收到请求，开始寻找文献

2026/1/15 15:47:31 已向机器人发送请求

1天前

达姆发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyScreening Natural Cholesterol Analogs to Assemble Self-Adjuvant Lipid Nanoparticles for Antigens Tagging Guided Therapeutic Tumor Vaccine